JP2008038011A5 - - Google Patents

Download PDF

Info

Publication number
JP2008038011A5
JP2008038011A5 JP2006213727A JP2006213727A JP2008038011A5 JP 2008038011 A5 JP2008038011 A5 JP 2008038011A5 JP 2006213727 A JP2006213727 A JP 2006213727A JP 2006213727 A JP2006213727 A JP 2006213727A JP 2008038011 A5 JP2008038011 A5 JP 2008038011A5
Authority
JP
Japan
Prior art keywords
phospholipid
silica gel
gel column
egg yolk
acetone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006213727A
Other languages
Japanese (ja)
Other versions
JP2008038011A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2006213727A priority Critical patent/JP2008038011A/en
Priority claimed from JP2006213727A external-priority patent/JP2008038011A/en
Publication of JP2008038011A publication Critical patent/JP2008038011A/en
Publication of JP2008038011A5 publication Critical patent/JP2008038011A5/ja
Pending legal-status Critical Current

Links

Description

リン脂質は動物、植物等の生体内に広く分布しており、その植物性、動物性のいずれもが利用価値の高い物質である。例えば、リン脂質はその界面活性機能から食品分野、化粧品分野、医薬品分野に利用されている。特にリン脂質含量が高純度に精製されたリン脂質は乳化特性、安全性に優れていることから脂質輸液など医薬品分野での利用開発が行われている。
従来のリン脂質の精製法としては、アセトン分別法(特許文献1)とシリカゲルカラム法(特許文献2)が挙げられる。例えば、卵黄由来リン脂質としては、割卵分離して得られた卵黄液を一旦乾燥して乾燥卵黄としたものに、アルコールを作用させてアルコール可溶性成分を抽出した後、該アルコールを除去して得られたものが知られている。精製卵黄リン脂質を得る方法としては、こうして得られた卵黄リン脂質を原料として、リン脂質はアセトンに不溶であるが、中性脂質はアセトンに可溶であるとの性質を利用する方法がよく知られている(アセトン分別法)。しかし、アセトン分別法は大規模な製造には適していないことや、アセトンの残留を減らすことが容易でないだけでなく、さらにその縮合体で特有の臭いを有するメシチルオキサイドやイソホロンなどの有害物質が生成することが、欠点として挙げられる。
一方、シリカゲルカラム法は原料の卵黄リン脂質をシリカゲルカラムに負荷し、クロロホルム−メタノール混液のメタノール含量を除々に増加して中性脂質を溶出した後、リン脂質を溶出させる方法がよく知られている(シリカゲルカラム法)。しかし、シリカゲルカラム法はクロロホルムやメタノールを使用することから、食品分野へは利用できない。また、シリカゲルカラム法は2種類の溶媒を濃度調整するため操作が煩雑である。
Phospholipids are widely distributed in living organisms such as animals and plants, and both plant and animal are highly useful substances. For example, phospholipids are used in the food field, cosmetic field, and pharmaceutical field because of their surface active function. In particular, phospholipids purified to a high purity with a high phospholipid content are excellent in emulsifying properties and safety, and are being developed for use in the pharmaceutical field such as lipid infusion.
Conventional methods for purifying phospholipids include acetone fractionation (Patent Document 1) and silica gel column method (Patent Document 2). For example, as egg yolk-derived phospholipid, the yolk liquid obtained by splitting egg yolk is dried once to obtain a dried egg yolk, and then alcohol is allowed to act to extract the alcohol-soluble component, and then the alcohol is removed. What is obtained is known. As a method for obtaining purified egg yolk phospholipid, a method utilizing the property that phospholipid is insoluble in acetone, but neutral lipid is soluble in acetone, using the egg yolk phospholipid thus obtained as a raw material is often used. Known (acetone fractionation method). However, the acetone fractionation method is not suitable for large-scale production, and it is not easy to reduce the residue of acetone, but also its condensate has a unique odor and harmful substances such as mesityl oxide and isophorone There can be generated, and as a disadvantage.
On the other hand, the silica gel column method is well known in which the raw material egg yolk phospholipid is loaded onto a silica gel column, the methanol content in the chloroform-methanol mixture is gradually increased to elute the neutral lipid, and then the phospholipid is eluted. (Silica gel column method). However, since the silica gel column method uses chloroform or methanol, it cannot be used in the food field. In addition, the silica gel column method is complicated to adjust the concentration of two types of solvents.

本発明は、従来全く想像すらされていなかった精製(製造)方法を用いて、高純度かつ有害な有機溶媒の混入のないリン脂質を提供することを可能にする。
(定義)
本明細書において使用する場合、用語「リン脂質」とは、リンを含む脂質をいう。リン脂質としては、ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルイノシトール、ホスファチジン酸が挙げられるが、これに限定されない。本明細書において使用する場合、リン脂質供給源としては、天然物原料、化学合成品、などが挙げられる。リン脂質供給源としての天然物原料としては、例えば、卵黄、卵巣、精巣、大豆、魚卵、魚介類(例えば、イカの可食部)などが挙げられるが、これに限定されない。
本明細書において使用する場合、用語「油脂成分」とは、天然または非天然のリン脂質供給源より有機溶媒によって抽出される成分であって、かつ、リン脂質を含有する成分をいう。
本明細書において使用する場合、用語「極性の低い有機溶媒」とは、シリカゲルカラムに負荷する物質を調製するために油脂成分と混合される有機溶媒であって、例えば、ヘキサンが挙げられるが、これに限定されない。
本明細書において使用する場合、用語「シリカゲル」とは、SiO・nHOの非晶質ケイ酸をいう。本発明において使用する場合、好ましくは、シリカゲルの粒子径は0.005mm〜10mmであり、球状でも破砕状でもよい。
本明細書において使用する場合、用語「抽出用有機溶媒」とは、本発明の方法によって高純度なリン脂質を製造するために極性の低い有機溶媒と混合されるための油脂成分を抽出によって調製する際に、その抽出に使用される有機溶媒をいう。抽出用有機溶媒としては、エタノール、ヘキサン、イソプロピルアルコール、酢酸エチル、アセトン、エーテル、クロロホルム、メタノール、あるいはこれらの混合物、が挙げられるが、これに限定されない。
また、本発明で製造される高純度リン脂質は、食品としての経口摂取が可能であることから、健康食品としての利用も可能である。
The present invention makes it possible to provide a high-purity phospholipid free from harmful organic solvents using a purification (manufacturing) method that has never been imagined.
(Definition)
As used herein, the term “phospholipid” refers to a lipid containing phosphorus. Phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid. As used herein, phospholipid sources include natural product raw materials, chemically synthesized products, and the like. Examples of the natural product raw material as a phospholipid supply source include, but are not limited to, egg yolk, ovary, testis, soybean, fish egg, and seafood (for example, edible portion of squid).
As used herein, the term “fat component” refers to a component that is extracted from a natural or non-natural phospholipid source by an organic solvent and contains a phospholipid.
As used herein, the term "lower organic polar solvents" is an organic solvent that is mixed with oil components in order to prepare the material loaded on a silica gel column, for example, there may be mentioned hexane However, the present invention is not limited to this.
As used herein, the term “silica gel” refers to an amorphous silicic acid of SiO 2 .nH 2 O. When used in the present invention, the silica gel preferably has a particle size of 0.005 mm to 10 mm and may be spherical or crushed.
As used herein, the term “organic solvent for extraction” refers to the extraction of oil components to be mixed with a less polar organic solvent to produce high purity phospholipids by the method of the present invention. In this case, it means an organic solvent used for the extraction. Examples of the organic solvent for extraction include, but are not limited to, ethanol, hexane, isopropyl alcohol, ethyl acetate, acetone, ether, chloroform, methanol, or a mixture thereof.
In addition, since the high-purity phospholipid produced in the present invention can be taken orally as a food, it can also be used as a health food.

本発明の薬学的組成物および飲食用組成物は、高度に精製されたリン脂質を有効成分として含有する。本発明の薬学的組成物および飲食用組成物は、活性成分としてリン脂質のみを単独で配合した形態、あるいはリン脂質以外の活性成分と組み合わせた形態において構成され、望ましくはリン脂質の含有量が20重量%以上、さらに好ましくは30重量%以上である。本発明の所望の効果を阻害しない範囲および程度であれば、他の公知の成分あるいは原材料を適宜に併用せしめてもよい。これらの例としてアスコルビン酸、アミノ酸、ペプチド、蛋白質およびこの分解物、各種糖質、澱粉およびこの分解物、ミネラル類、ビタミンE、トコフェロール、フィトステロール、カテキン、グァバ葉等のポリフェノール類等およびこれらの誘導体を挙げることができるが、これらに限定されない。


The pharmaceutical composition and the composition for eating and drinking of the present invention contain highly purified phospholipid as an active ingredient. Pharmaceutical compositions and dietary compositions of the present invention, a form of phospholipid only blended alone as the active ingredient, or is Oite constructed in the form state combined with an active ingredient other than a phospholipid, preferably a phospholipid The content is 20% by weight or more, more preferably 30% by weight or more. Other known components or raw materials may be used in combination as appropriate as long as they do not interfere with the desired effects of the present invention. Examples thereof include ascorbic acid, amino acids, peptides, proteins and degradation products thereof, various sugars, starches and degradation products thereof, minerals, vitamin E, tocopherol, phytosterols, polyphenols such as catechin and guava leaves, and derivatives thereof. Although not limited to these, it is not limited to these.


JP2006213727A 2006-08-04 2006-08-04 Method for producing highly pure phospholipid Pending JP2008038011A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006213727A JP2008038011A (en) 2006-08-04 2006-08-04 Method for producing highly pure phospholipid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006213727A JP2008038011A (en) 2006-08-04 2006-08-04 Method for producing highly pure phospholipid

Publications (2)

Publication Number Publication Date
JP2008038011A JP2008038011A (en) 2008-02-21
JP2008038011A5 true JP2008038011A5 (en) 2009-08-27

Family

ID=39173410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006213727A Pending JP2008038011A (en) 2006-08-04 2006-08-04 Method for producing highly pure phospholipid

Country Status (1)

Country Link
JP (1) JP2008038011A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7357471B2 (en) * 2019-06-13 2023-10-06 キユーピー株式会社 Phospholipid purification method
TWI815067B (en) 2019-12-26 2023-09-11 日商瑪魯哈日魯股份有限公司 Fish egg lipid composition containing phospholipids combined with polyunsaturated fatty acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2909508B2 (en) * 1989-02-14 1999-06-23 マルハ株式会社 Krill phospholipid fractionation method
JP2646421B2 (en) * 1993-10-12 1997-08-27 日清製油株式会社 Obesity prevention agent
JP3009017B2 (en) * 1993-10-19 2000-02-14 日清製油株式会社 Blood lipid lowering agent

Similar Documents

Publication Publication Date Title
Girgih et al. In vitro antioxidant properties of hemp seed (Cannabis sativa L.) protein hydrolysate fractions
Barrow et al. Marine nutraceuticals and functional foods
KR101840508B1 (en) Beautiful-skin-promoting agent and use thereof
JP2006507846A (en) Marine phospholipid composition
DE60317639T3 (en) COMPOSITIONS CONTAIN N-ACYL-PHOSPHATIDYL-ETHANOLAMINE AND / OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDINIC ACIDS OR LYSOPHOSPHATIDINIC ACIDS
JP5842640B2 (en) Phosphodiesterase 3 inhibitor
US20160256513A1 (en) Synergized turmeric
KR102192712B1 (en) An animal feed composition comprising phlorotannin and product for animal
JP2008038011A5 (en)
Aslan et al. Nigella sativa improves the carbon tetrachloride-induced lung damage in rats through repression of erk/akt pathway
Broniatowski et al. Antagonistic effects of α-tocopherol and ursolic acid on model bacterial membranes
Pagliaro et al. Sustainably sourced olive polyphenols and omega-3 marine lipids: A synergy fostering public health
KR101404460B1 (en) Cosmetics composition comprising fish extract
JP2015096498A (en) Ages decomposer
ES2684178B1 (en) Obtaining phospholipids from cephalopods by sequential extraction with supercritical fluids
KR20050088153A (en) Composition and method for treating age-related disorders
JP2016013981A (en) Tubulin polymerization activity regulator, food and agent comprising the same, and method of producing tubulin polymerization activity regulator
JP6513485B2 (en) Odor masking agent and capsule
Hassanien Composition and antiradical power of Syzygium aromaticum lipids
KR20230173476A (en) Antioxidant composition comprising a mixture of royal jelly and propolis powder
Ćirić et al. Valorisation of Raspberry Seeds in Cosmetic Industry-Green Solutions
Shahidi et al. Dietary Lipid Supplements
Rodríguez-Pólit et al. Chemical Properties and Biological Activity of Bee Pollen
WO2021131872A1 (en) Oral composition
JP6553849B2 (en) Bad breath